Evommune (NYSE:EVMN) CFO Kyle Carver Sells 18,175 Shares of Stock

Evommune, Inc. (NYSE:EVMN) CFO Kyle Carver sold 18,175 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $22.84, for a total transaction of $415,117.00. Following the completion of the transaction, the chief financial officer directly owned 59,335 shares of the company’s stock, valued at approximately $1,355,211.40. This trade represents a 23.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Evommune Stock Down 5.1%

NYSE EVMN opened at $22.04 on Tuesday. Evommune, Inc. has a 1 year low of $13.89 and a 1 year high of $33.20. The stock has a market cap of $793.70 million and a PE ratio of -2.32. The business has a 50 day moving average price of $24.12.

Evommune (NYSE:EVMN) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.19. On average, analysts forecast that Evommune, Inc. will post -2.83 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Stifel Nicolaus assumed coverage on shares of Evommune in a research note on Friday, May 1st. They set a “buy” rating and a $54.00 target price on the stock. Morgan Stanley lifted their target price on shares of Evommune from $54.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Royal Bank Of Canada reissued an “outperform” rating and set a $48.00 price objective on shares of Evommune in a report on Friday, April 10th. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Evommune in a research report on Tuesday, May 26th. Finally, Oppenheimer started coverage on shares of Evommune in a research report on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $49.25.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in EVMN. China Universal Asset Management Co. Ltd. bought a new position in shares of Evommune in the fourth quarter worth about $34,000. Strs Ohio bought a new position in shares of Evommune in the first quarter worth about $41,000. The Manufacturers Life Insurance Company bought a new position in shares of Evommune in the fourth quarter worth about $179,000. XTX Topco Ltd bought a new position in shares of Evommune in the fourth quarter worth about $321,000. Finally, Oxford Asset Management LLP bought a new position in shares of Evommune in the fourth quarter worth about $335,000.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.